[4-Aminoquinoline-sensitivity of Plasmodium falciparum in Madagascar. III. Studies in three regions of the interior].
Among 273 malarial patients recruited through passive detection, 177 in vivo tests were performed in Andekaleka and Ankazobe and 23 in vitro tests in Ifanadiana, and Ankazobe (inland of Madagascar). In vivo, chloroquine failed within 7 days at 10 mg/kg in 28/86 patients, at 25 mg/kg in 7/34 and amodiaquine failed in 5/55 with 10 mg/kg and in 0/14 with 25 mg/kg. In vitro, the semi-microtest revealed resistance to chloroquine of 1/23 isolates (IC50 = 750 nM/1) but high sensitivity to amodiaquine, dichlorquinazine and piperaquine of all studied isolates (max IC50 = 92 nM/1).
D000634:Aminoquinolines / Q000627:therapeutic use*; D000655:Amodiaquine / Q000627:therapeutic use; D000962:Antimalarials; D002738:Chloroquine / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D008270:Madagascar; D008288:Malaria / Q000188:drug therapy* / Q000453:epidemiology; D010879:Piperazines / Q000627:therapeutic use; D010963:Plasmodium falciparum / Q000187:drug effects*; D011804:Quinolines / Q000627:therapeutic use
D000634:Aminoquinolines; D000962:Antimalarials; D010879:Piperazines; D011804:Quinolines; C043112:dichlorquinazine; D000655:Amodiaquine; D002738:Chloroquine; C034759:piperaquine
Sensibilité aux amino-4-quinoleines de Plasmodium falciparum a Madagascar: III. Etudes en trois regions de l'interieur.